Cv Sciences Stock News

CV Sciences, Inc. (OTCMKTS:CVSI) Investment analysts at Cantor Fitzgerald issued their FY2021 EPS estimates for shares of CV Sciences in a report released on Monday, December 13th. Cantor Fitzgerald analyst P. Zuanic forecasts that the company will post earnings per share of ($0.09) for the year. Cantor Fitzgerald has a Neutral rating and a []

CV Sciences (OTCMKTS:CVSI) had its price objective lowered by research analysts at Cantor Fitzgerald from $0.42 to $0.17 in a research note issued to investors on Friday, Analyst Ratings Network reports. The firm currently has a neutral rating on the stock. Cantor Fitzgeralds target price points to a potential upside of 13.33% from the stocks []

Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and []

One of the keys to finding new opportunities is discovering deep value where investors have tossed everything overboard in a particular theme with no regard for long-term performance potential. Find those opportunities and you unlock enormous stores of long-term low risk return potential. The CBD space may offer such an opportunity right now. The [] The post Is it Time to Focus on CBD Stocks Again (YCBD, RLBD, NEPT, JAZZ, TPB, MJNA, CVSI) appeared first on Wall Street PR .

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has appointed Haskell & White LLP ("H&W") as the Company''s new independent registered public accounting firm.

CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement am

CV Sciences, Inc. (OTCQB:CVSI), a supplier and manufacturer of hemp cannabidiol (CBD) products, announced its financial results for the quarter on Monday, Nov 15. Third Quarter 2021 and Recent Financ

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 100.00% and -7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in the aggregate original principal amount of $1.06 million. Upon our filing with the Securities and Exchange Commission of an additional prospectus supplement and supplemental indenture and our satisfaction of certain other closing conditions, we may elect to offer and sell up to and additional $4,240,000 in aggregate principal amount of notes at additional closings, resulting in potential gross proceeds for this offering and such additional offerings, of approximately $5.3 million.

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q3 2021 Earnings Conference Call - Earnings Call Transcript

CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cann